NCI Considers ‘Decentralization’ Of Group C To Provide Wider Access, Local Flexibility
In Brief: Broder Invokes Cancer Act Provision To Inform Hammer, Bush Of Potential Damage Of 32% Cut
Lasagna Committee Report Advocates Faster Drug approval, Insurance Coverage For Investigational Drugs, Ancillary Costs
Don’t Blame FDA For All Problems, Broder Says
Outside Experts Might Lengthen NDA Approval, Peck Asserts
Freement Lists Steps For Dealing With Disadvantaged
Trending Stories
- Gynecology’s deadly surprise:
Cancers are frequently missed prior to routine procedures - Amy Reed, physician and patient who “moved mountains” to end widespread use of power morcellation, dies at 44
- Weeks before death from sarcoma, Norm Coleman reflected on his career in radiation oncology and addressing health disparities
- Rathmell announces new cancer screening network, new NCI virtual clinical trials office
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- ASCO 2024 special awards go to: Winn, Bhatia, Dale, Siu, Pierce, Kantoff, Newman, Gopal, Mutebi, Feldman, Gorlick, Pietenpol, Abrahm, Giordano, Vaz-Luis